xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

204

KUANetal.

TABLE XXII.A.1 Evidence surrounding the management of sinonasal ITAC. Study Year LOE Study design Study groups

Clinical endpoints Conclusion

Huang et al. 1154

Patients treated more recently presented with older mean age have lower local recurrence rate, improved 5-year OS, and are most frequently treated via EEA Endoscopic management of sinonasal ITAC is safe and effective, with reduced morbidity and lower complication rates compared to open and combined approaches 2. Induction chemotherapy (PFL) should be used for patients with P53 functionality Factors associated with poor prognosis were age at presentation > 54 years old, histology subtype (mucinous signet-ring vs. solid or mucinous alveolar goblet vs. papillary, colonic, mixed), cranial resection, positive margins, and advanced pT stage 1. Sphenoid lateral or posterior walls invasion can be considered as poor prognostic factors, with survival rates much more comparable to dura and/or cerebral extension rather than other sphenoidal subsites 1. P53 status represents a biomarker to predict response to chemotherapy in ITAC

1. OS 2. Local, regional, and distant recurrence 3. Stratification of

1126 cases of sinonasal ITAC, surgically treated with open, EEA, or combined approach

2021 2

Systematic

reviewand meta analysis

patients according to the enrollment year

Meccariello et al. 259

2016 2

Systematic review

947 cases of sinonasal ITAC, surgically treated with EEA, external or combined approach

1. OS 2. DFS 3. LRFS 4. To analyze

morbidity rates, major and minor complications in EEA, open, and combined approaches therapeutic guide for the use of chemotherapy drugs

Licitra et al. 1151

Status of P53 as a

2004 2

Clinical trial

30 cases of sinonasal ITAC treated with primary chemotherapy followed by CFR and postoperative RT when necessary 389 cases of sinonasal ITAC surgically treated with EEA with or without transnasal craniectomy or a combined CFR

Ferrari et al. 16

2022 3

Prospective

1. OS 2. RFS (LRFS, RRFS, DRFS) 3. Multivariable analysis 4. To create nomograms based on multivariable models

multicenter case–control study

Fiaux-Camous et al. 1145

1. To evaluate whether the patients’ stratification

223 cases of sinonasal ITAC not previously treated, without evidence of positive

2017 3

Multicenter

prospective cohort with systematic review

according to the local extension of tumor in the 7th edition of the AJCC/UICC TNM classification is associated with prognosis for ethmoidal ITAC prognostic risk prediction model for OS among patients undergoing endoscopy surgery for ethmoid ITAC

neck nodes, who were treated with EEA

2. Two subsites might be classified as pT4b

2. To develop a

(Continues)